photo pending
CJC-1295 appears in scientific literature and commercial research catalogs under several related names. One of the most important distinctions is whether a material is described as CJC-1295 with DAC or CJC-1295 without DAC.
Although these terms are sometimes used as though they describe two versions of the same material, the terminology requires more careful interpretation. The presence or absence of the Drug Affinity Complex (DAC) represents a meaningful structural distinction and can affect the interpretation of experimental results.
What Does DAC Mean in CJC-1295 Research?
DAC stands for Drug Affinity Complex.
DAC stands for Drug Affinity Complex. It describes a chemical modification designed to promote covalent binding between a peptide analog and serum albumin.
The CJC-1295 compound described in early published research incorporated a reactive maleimide-containing group. Experimental studies demonstrated an association of the resulting compound with albumin and investigated how this modification altered its persistence relative to shorter-lived GHRH-derived peptides.
DAC should therefore be understood as a structural and pharmacokinetic modification, rather than simply part of the compound’s name.
Why “CJC-1295 Without DAC” Potentially Confusing
Research suppliers widely use the expression CJC-1295 without DAC. However, researchers should be careful when connecting material sold under this name with published CJC-1295 studies.
Much of the primary scientific literature describing CJC-1295 investigated the DAC-containing compound.
Materials labeled CJC-1295 without DAC are also frequently referred to as Modified GRF (1–29) or Mod GRF (1–29). These names refer to a modified 29-amino-acid GHRH-derived sequence lacking the albumin-binding DAC modification.
Consequently, a publication referring simply to “CJC-1295” should not automatically be assumed to have investigated the non-DAC material.
Why This Distinction Matters When Reading Studies
Correct compound identification is essential when comparing peptide research.
For example, a study by Jette and colleagues investigated CJC-1295, a tetrasubstituted hGRF(1–29) derivative with an additional maleimide-based modification. The researchers demonstrated an association between the compound and serum albumin and investigated the resulting changes in molecular persistence.
Later investigations by Teichman and colleagues examined the pharmacokinetic characteristics of this long-acting CJC-1295 compound.
These studies provide useful information about DAC-modified CJC-1295, but their findings should not automatically be attributed to material lacking the DAC functionality.
The difference becomes particularly important when evaluating:
- compound identity;
- peptide sequence and chemical modifications;
- albumin association;
- experimental pharmacokinetics;
- analytical results; and
- whether a publication actually corresponds to the research material being studied.
CJC-1295 Terminology in Scientific Literature
Researchers examining CJC-1295 literature may encounter several terms, including CJC-1295, CJC-1295 DAC, CJC-1295 with DAC, DAC-GRF, CJC-1295 without DAC, Modified GRF (1–29) and Mod GRF (1–29).
These terms should not be treated as automatically interchangeable.
When reviewing a paper, the experimental methods and description of the compound are more informative than the name alone. Researchers can check whether the material incorporates a maleimide-containing DAC group, whether albumin conjugation is described, and which peptide sequence was investigated.
This provides a more reliable method of identifying the experimental compound than relying solely on terminology.
Can Research on CJC-1295 DAC Be Applied to CJC-1295 Without DAC?
No, not by default. It is not possible to simply transfer findings that rely on DAC-mediated albumin attachment, longer molecular persistence, or other features generated by the DAC alteration to a non-DAC peptide.
Not automatically.
A study should first be assessed to determine exactly which molecular form was investigated. Findings that depend upon DAC-mediated albumin association, extended molecular persistence or other properties produced by the DAC modification cannot simply be transferred to a non-DAC peptide.
Likewise, research involving Modified GRF (1–29) should not automatically be described as evidence specifically concerning DAC-modified CJC-1295.
Maintaining this distinction improves the accuracy of scientific citations and prevents structurally different research materials from being grouped under the same name.
Why The Exact Terminology of With or Without DAC Matters in Research: Summary
Researchers should ask which compound was actually investigated.
Sequence information, chemical modification, analytical documentation, and the experimental methods reported in the original publication can be used to determine whether the research concerns a DAC-containing or non-DAC GHRH analog.
This distinction is particularly important when interpreting older CJC-1295 literature because the name “CJC-1295” by itself does not necessarily correspond to materials now marketed as CJC-1295 without DAC.
Accurate nomenclature allows research findings to be attributed to the correct molecular entity and reduces the risk of comparing chemically distinct compounds.
Frequently Asked Questions about CJC-1295
Drug Affinity Complex is referred to as DAC. It refers to a chemical modification intended to promote covalent binding between the peptide analog and serum albumin in published CJC-1295 research.
No. A structural distinction between the materials is represented by the DAC modification. Therefore, while evaluating experimental results, researchers should differentiate between DAC-containing CJC-1295 and non-DAC GHRH-derived peptides.
Research suppliers frequently use the phrases CJC-1295 without DAC and Modified GRF (1–29) interchangeably. Instead of depending only on naming standards, researchers should verify the peptide sequence and chemical specification.
Early scientific publications using the name CJC-1295 generally investigated the DAC-containing analogue. This means the name CJC-1295 in a publication should not automatically be assumed to refer to a non-DAC peptide.
Researchers should review the methods section, the molecular description, and the reported sequence or chemical modification. References to a maleimide-containing group, albumin conjugation or a Drug Affinity Complex usually indicate the DAC-modified compound.
Albumin association is a defining characteristic of the DAC-modified compound described in the original CJC-1295 literature. Its presence helps distinguish those studies from research involving non-DAC GHRH-derived peptides.
No. Experimental findings should be attributed to the specific molecular form investigated. Structural modification can affect properties such as molecular persistence, protein association and experimental pharmacokinetics.
Researchers can match published findings to the appropriate experimental chemical with the aid of accurate nomenclature. This lessens the possibility of citing or comparing chemically different materials as if they were the same.
Scientific references
- 1 Jette L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052–3058. doi:10.1210/en.2004-1606. https://pubmed.ncbi.nlm.nih.gov/15817669/
- 2 Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. doi:10.1210/jc.2005-1536. https://pubmed.ncbi.nlm.nih.gov/16352683/
- 3 Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797. doi:10.1210/jc.2006-1702. https://pubmed.ncbi.nlm.nih.gov/17018654/
Research-use disclaimer: For research and laboratory use only. Not for human or animal consumption.